These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are currently highly successful.
Right now, there are a few reasons to believe that Eli Lilly has the upper hand in this competitive clash. Those reasons support buying its stock, assuming you don't want to invest in both companies. Here are three things that are giving Lilly an edge.
It's well-known that sales of new weight-loss drugs are powering earnings growth and share-price appreciation for both companies. Demand for those medicines, like Lilly's Zepbound and Novo Nordisk's Wegovy, is so intense in the U.S. that for months neither company has been able to manufacture enough to meet patient Demand. In the second quarter alone, Zepbound brought in more than $1.2 billion in revenue, making it a blockbuster drug.
Source Fool.com
